查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370935

罕見疾病基因檢測市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按疾病類型、按專業、按技術、按最終用戶、按地區、競爭細分

Rare Disease Genetic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Disease Type, By Speciality By Technology, By End User, By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022年，全球罕見疾病基因檢測市值為7.8983億美元，預計在預測期內將出現強勁成長，預計年複合成長率（CAGR）為8.04%，到2028年預計將達到12.4963億美元。罕見疾病基因檢測涉及對導致罕見疾病的基因突變或改變進行診斷。這些疾病的盛行率較低，僅影響一小部分人口。它們通常是由基因突變或特定基因的改變引起的。罕見疾病的基因檢測分析個體的 DNA，以識別可能導致其症狀或病症的異常或突變。這有助於準確診斷、了解疾病的根本原因並指導個人化治療策略。罕見疾病基因檢測採用多種技術，包括次世代定序（NGS），它可以同時分析多個基因或整個基因組。該技術提高了基因檢測的效率和準確性，能夠檢測罕見的基因突變。

主要市場促進因素

罕見病患疾病率的上升推動市場成長：罕見病患疾病率的上升是全球罕見疾病基因檢測市場的重要驅動力。罕見疾病在人群中的盛行率估計為 3.5-5.9%，全球約有 260-4.4 億人。隨著對遺傳學和罕見疾病的了解不斷加深，基因檢測對於準確和早期診斷變得至關重要。它能夠識別與罕見疾病相關的特定基因突變，確認診斷並制定有針對性的治療計劃。醫療保健提供者和患者對罕見疾病的認知不斷提高，導致對準確、及時診斷的需求更高。患者及其家人更有可能尋求疑似罕見疾病的基因檢測，從而促進了市場成長。精準醫學的概念根據個人的基因組成客製化醫療服務，進一步推動了對基因檢測的需求。

市場概況
預測期 2024-2028
2022 年市場規模 78983萬美元
2028 年市場規模 124963萬美元
2023-2028 年年複合成長率 8.04%
成長最快的細分市場 研究實驗室和 CRO
最大的市場 北美洲

對個人化醫療的需求不斷成長推動市場成長：對個人化醫療的需求不斷成長對全球罕見疾病基因檢測市場產生了重大影響。個人化醫療涉及根據個別患者特徵（包括基因組成）客製化醫療治療。它根據遺傳資訊預測哪種治療最有效。基因檢測對於識別罕見疾病的基因突變、確認診斷並了解原因至關重要。個人化醫療旨在針對疾病的根本原因，因此基因檢測對於客製化治療至關重要。基因檢測可以實現精確、早期的罕見疾病診斷，對於症狀模糊或重疊的疾病尤其重要。準確的診斷可確保適當且有效的治療方案。基因檢測還可以識別潛在的藥物標靶，預測治療反應並指導治療選擇，這對於標準治療有限的罕見疾病尤其重要。

提高意識和宣傳推動市場成長：對罕見疾病的認知和宣傳不斷提高有助於全球罕見疾病基因檢測市場的成長。大約 7,000 種罕見疾病影響著 2500-3000 萬美國人，從而提高了人們的認知。宣傳工作提高了基因檢測在管理罕見疾病方面的形象，推動了對檢測服務的需求。意識和宣傳的提高導致患者、醫療保健提供者和政策制定者更多地考慮基因檢測。隨著人們對罕見疾病和基因檢測重要性的認知不斷提高，患者尋求基因檢測來進行準確診斷和個人化治療。倡導活動強調早期診斷對於改善患者治療結果的重要性，從而導致對檢測服務的更高需求。倡導團體、醫療保健提供者和研究人員之間的合作改善了基因檢測的獲取和資金，促進了市場的成長。

主要市場挑戰

診斷的複雜性帶來了測試挑戰：罕見疾病的複雜性可能導致延遲或誤診。醫療保健提供者可能很難確定症狀的根本原因，從而導致不正確的治療或介入。罕見疾病具有異質性症狀，並且往往缺乏標準化的診斷標準，這使得基因檢測具有挑戰性。罕見疾病的遺傳基礎可能涉及多個基因和變異，使精確的突變識別變得複雜。準確識別罕見疾病基因突變需要先進的檢測技術和生物資訊分析。

有限的知識和意識阻礙了檢測的採用：醫療保健提供者的意識有限阻礙了對罕見疾病進行基因檢測。對罕見疾病臨床表現和基因圖譜缺乏熟悉導致基因檢測的利用不足。由於知識有限而誤診導致不適當的治療。意識有限會影響基因檢測的選擇，因為提供者可能無法識別與特定罕見疾病相關的遺傳標記。認知有限也減緩了罕見疾病的研究進展和測試開發。

道德和隱私問題影響檢測的採用：道德和隱私問題影響罕見疾病基因檢測的採用。獲得基因檢測的知情同意很複雜，尤其是對於罕見疾病。圍繞基因資料的隱私和安全問題阻礙了測試參與。基因檢測可能會揭示意想不到的發現，造成道德兩難。遺傳資料也可能影響未同意進行檢測的家庭成員。道德考慮受到文化和宗教信仰的影響，需要仔細的測試管理。

主要市場趨勢

直接面對消費者（DTC）檢測的成長：儘管與血統或健康特徵等其他基因檢測領域相比，DTC 檢測在全球罕見疾病基因檢測市場中的成長相對有限，但它發揮了一定作用。 DTC 測試為消費者提供遺傳訊息，有可能識別與罕見疾病相關的標記。即使不專門針對罕見疾病，DTC 檢測也能提高一般遺傳學和健康意識。 DTC 測試可以識別與疾病相關的罕見遺傳變異。一些公司提供將遺傳資料貢獻給研究資料庫的選項，以幫助罕見疾病的研究和發現。道德問題和監管監督會影響 DTC 測試的準確性和影響。

細分市場洞察

疾病類型洞察：內分泌和代謝領域在 2022 年罕見疾病基因檢測市場中佔據主導地位，預計將繼續成長。此類中的許多罕見疾病都有明確的遺傳基礎，其突變會影響荷爾蒙的產生和代謝。基因檢測有助於早期診斷和介入。遺傳訊息指導個人化治療計劃，針對特定的基因突變並改善結果。

技術洞察：次世代定序 (NGS) 在 2022 年罕見疾病基因檢測市場佔據主導地位，並且可能會繼續成長。 NGS 徹底改變了基因檢測，提供速度、經濟性、準確性以及大型基因資料集的分析。它有助於識別罕見的基因突變，提高診斷和治療的準確性。

專業見解：分子遺傳學檢測在 2022 年罕見疾病基因檢測市場中佔據主導地位，預計將繼續成長。分子檢驗分析 DNA、RNA 或蛋白質，診斷罕見疾病、監測進展並識別風險。

最終用途產業洞察：研究和合約研究組織 (CRO) 在 2022 年罕見疾病基因檢測市場中佔據主導地位，並且可能會繼續成長。他們開發基因測試、進行試驗並提供測試服務。研究和 CRO 研究罕見疾病的遺傳基礎、開發治療方法並改善診斷和管理。

區域洞察

北美引領全球罕見疾病基因檢測市場，主要是美國和加拿大。這些國家擁有先進的醫療基礎設施，支持基因檢測技術的開發、採用和整合。該地區罕見疾病的高盛行率是由於人口老化和意識增強等因素造成的。該地區突出的醫療保健環境支持基因檢測的成長和採用。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：定價分析

第 6 章：全球罕見疾病基因檢測市場展望

  • 市場規模及預測
    • 按價值和數量
  • 市佔率及預測
    • 依疾病類型（神經系統疾病、心血管疾病）
    • 按專業（分子、生物化學）
    • 按技術（NGS、基於 PCR）
    • 按最終用戶（研究實驗室和 CRO、醫院和診所、診斷實驗室）
    • 按公司分類 (2022)
    • 按地區
  • 產品市場地圖

第 7 章：北美罕見疾病基因檢測市場展望

  • 市場規模及預測
    • 按價值和數量
  • 市佔率及預測
    • 依疾病類型
    • 專業
    • 科技
    • 按最終用途行業
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 8 章：歐洲罕見疾病基因檢測市場展望

  • 市場規模及預測
    • 按價值和數量
  • 市佔率及預測
    • 依疾病類型
    • 按專業
    • 依技術
    • 按最終用途行業
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第9章 ：亞太地區罕見疾病基因檢測市場展望

  • 市場規模及預測
    • 按價值和數量
  • 市佔率及預測
    • 依疾病類型
    • 按專業
    • 依技術
    • 按最終用途行業
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第10章 ：南美罕見疾病基因檢測市場展望

  • 市場規模及預測
    • 按價值和數量
  • 市佔率及預測
    • 依疾病類型
    • 按專業
    • 依技術
    • 按最終用途行業
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第11章：中東和非洲罕見疾病基因檢測市場展望

  • 市場規模及預測
    • 按價值和數量
  • 市佔率及預測
    • 依疾病類型
    • 按專業
    • 依技術
    • 按最終用途行業
    • 按國家/地區
  • MEA：國家分析
    • 南非罕見疾病基因檢測
    • 沙烏地阿拉伯罕見疾病基因檢測
    • 阿拉伯聯合大公國罕見疾病基因檢測

第 12 章：市場動態

  • 促進要素
  • 挑戰

第 13 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 14 章：大環境分析

第 15 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第16章：競爭格局

  • 商業概覽
  • 公司概況
  • 產品與服務
  • 財務（上市公司）
  • 最近的發展
  • SWOT分析
    • Centogene NV
    • Invitae Corp.
    • 3billion, Inc.
    • Arup Laboratories
    • Eurofins Scientific
    • Strand Life Sciences
    • Ambry Genetics
    • Perkin Elmer, Inc.
    • Realm IDX, Inc.
    • Macrogen, Inc.

第 17 章：策略建議

簡介目錄
Product Code: 15833

The Global Rare Disease Genetic Testing Market was valued at USD 789.83 Million in 2022 and is expected to experience robust growth during the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 8.04% and expected to reach USD 1249.63 Million through 2028. Rare Disease Genetic Testing involves the diagnosis of genetic mutations or alterations responsible for rare diseases. These diseases have a low prevalence, affecting only a small percentage of the population. They are often caused by genetic mutations or alterations in specific genes. Genetic testing for rare diseases analyzes an individual's DNA to identify abnormalities or mutations that may be causing their symptoms or condition. This aids in accurate diagnosis, understanding the underlying cause of the disease, and guiding personalized treatment strategies. Various techniques are used for rare disease genetic testing, including next-generation sequencing (NGS), which allows the analysis of multiple genes or the entire genome simultaneously. This technology enhances the efficiency and accuracy of genetic testing, enabling the detection of rare genetic mutations.

Key Market Drivers

Increasing Prevalence of Rare Diseases Drives Market Growth: The rising prevalence of rare diseases is a significant driver for the global rare disease genetic testing market. The prevalence rate of rare diseases in the population was estimated at 3.5-5.9%, translating to approximately 260-440 million people globally. As understanding of genetics and rare diseases improves, genetic testing becomes crucial for accurate and early diagnosis. It enables the identification of specific genetic mutations associated with rare diseases, confirming diagnoses, and enabling targeted treatment plans. Increased awareness of rare diseases among healthcare providers and patients has led to higher demand for accurate and timely diagnosis. Patients and their families are more likely to seek genetic testing for suspected rare diseases, contributing to market growth. The concept of precision medicine, which tailors medical care to an individual's genetic makeup, further drives the demand for genetic testing.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 789.83 Million
Market Size 2028USD 1249.63 Million
CAGR 2023-20288.04%
Fastest Growing SegmentResearch Laboratories & CROs
Largest MarketNorth America

Increasing Demand for Personalized Medication Drives Market Growth: The growing demand for personalized medicine significantly influences the global rare disease genetic testing market. Personalized medicine involves tailoring medical treatment to individual patient characteristics, including genetic makeup. It anticipates which treatments will be most effective based on genetic information. Genetic testing is crucial for identifying genetic mutations underlying rare diseases, confirming diagnoses, and understanding their causes. Personalized medicine aims to target disease root causes, making genetic testing essential for treatment tailoring. Genetic testing enables precise and early rare disease diagnosis, especially important for conditions with vague or overlapping symptoms. Accurate diagnosis ensures appropriate and effective treatment options. Genetic testing also identifies potential drug targets, predicts treatment responses, and guides therapy selection, particularly important for rare diseases with limited standard treatments.

Increasing Awareness and Advocacy Drive Market Growth: Rising awareness and advocacy for rare diseases contribute to the growth of the global rare disease genetic testing market. Approximately 7,000 rare diseases affect 25-30 million Americans, leading to increased awareness. Advocacy efforts raise the profile of genetic testing in managing rare diseases, driving demand for testing services. Increased awareness and advocacy lead to greater genetic testing consideration among patients, healthcare providers, and policymakers. As awareness spreads about rare diseases and the importance of genetic testing, patients seek genetic testing for accurate diagnosis and personalized treatment. Advocacy initiatives emphasize early diagnosis significance for improved patient outcomes, leading to higher demand for testing services. Collaborations between advocacy groups, healthcare providers, and researchers improve genetic testing access and funding, contributing to market growth.

Key Market Challenges

Diagnostic Complexity Poses Testing Challenges: Rare diseases' complexity can lead to delayed or misdiagnosis. Healthcare providers may struggle to identify underlying causes of symptoms, leading to incorrect treatments or interventions. Rare diseases have heterogeneous symptoms and often lack standardized diagnostic criteria, making genetic testing challenging. Rare diseases' genetic basis can involve multiple genes and variants, complicating precise mutation identification. Advanced testing technologies and bioinformatics analysis are required to identify rare disease genetic mutations accurately.

Limited Knowledge and Awareness Hinders Testing Adoption: Limited awareness among healthcare providers hinders genetic testing consideration for rare diseases. Lack of familiarity with rare disease clinical presentations and genetic profiles leads to underutilization of genetic testing. Misdiagnosis due to limited knowledge results in inappropriate treatments. Limited awareness affects genetic testing selection, as providers may not recognize genetic markers associated with specific rare diseases. Limited awareness also slows rare disease research progress and test development.

Ethical and Privacy Concerns Impact Testing Uptake: Ethical and privacy concerns affect rare disease genetic testing adoption. Obtaining informed consent for genetic testing is complex, especially for rare diseases. Privacy and security concerns around genetic data discourage testing participation. Genetic testing may reveal unexpected findings, creating ethical dilemmas. Genetic data may also affect family members who have not consented to testing. Ethical considerations are influenced by cultural and religious beliefs, requiring careful testing management.

Key Market Trends

Growth of Direct-to-Consumer (DTC) Testing: While DTC testing's growth in the global rare disease genetic testing market is relatively limited compared to other genetic testing areas, such as ancestry or health traits, it plays a role. DTC tests empower consumers with genetic information, potentially identifying markers associated with rare diseases. Even if not exclusively for rare diseases, DTC testing increases general genetics and health awareness. DTC tests can identify rare genetic variants associated with conditions. Some companies offer options to contribute genetic data to research databases, aiding rare disease research and discoveries. Ethical concerns and regulatory oversight impact DTC testing's accuracy and implications.

Segmental Insights

Disease Type Insights: The Endocrine & Metabolism segment dominated the 2022 Rare Disease Genetic Testing market and is projected to continue growing. Many rare diseases in this category have clear genetic bases, with mutations affecting hormone production and metabolism. Genetic testing aids early diagnosis and intervention. Genetic information guides personalized treatment plans, targeting specific genetic mutations and improving outcomes.

Technology Insights: Next-Generation Sequencing (NGS) dominated the 2022 Rare Disease Genetic Testing market and will likely continue growing. NGS revolutionizes genetic testing, offering speed, affordability, accuracy, and the analysis of large genetic datasets. It aids the identification of rare genetic mutations and enhances diagnosis and treatment precision.

Specialty Insight: Molecular genetic tests dominated the 2022 Rare Disease Genetic Testing market and are predicted to continue growing. Molecular tests analyze DNA, RNA, or proteins, diagnosing rare diseases, monitoring progression, and identifying risk.

End-Use Industry Insights: Research & Contract Research Organizations (CROs) dominated the 2022 Rare Disease Genetic Testing market and will likely continue growing. They develop genetic tests, conduct trials, and offer testing services. Research & CROs study genetic bases of rare diseases, develop treatments, and improve diagnosis and management.

Regional Insights

North America leads the Global Rare Disease Genetic Testing Market, primarily the United States and Canada. These countries possess advanced healthcare infrastructure supporting genetic testing technology development, adoption, and integration. The region's high rare disease prevalence results from factors like an aging population and increased awareness. This region's prominent healthcare landscape supports genetic testing growth and adoption.

Key Market Players

  • Centogene N.V.
  • Invitae Corp.
  • 3billion, Inc.
  • Arup Laboratories
  • Eurofins Scientific
  • Strand Life Sciences
  • Ambry Genetics
  • Perkin Elmer, Inc.
  • Realm IDX, Inc.
  • Macrogen, Inc.
  • Baylor Genetics

Report Scope:

In this report, the Global Rare Disease Genetic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Rare Disease Genetic Testing Market, By Disease Type:

  • Neurological Disease
  • Immunological Disorders
  • Hematology Diseases
  • Endocrine & Metabolism Diseases
  • Cancer
  • Musculoskeletal Disorders
  • Cardiovascular Disorders (CVDs)
  • Dermatology Disease
  • Others

Global Rare Disease Genetic Testing Market, By Speciality:

  • Molecular Genetic Tests
  • Chromosomal Genetic Tests
  • Biochemical Genetic Tests

Global Rare Disease Genetic Testing Market, By Technology:

  • Next-Generation Sequencing (NGS)
  • Whole Exome Sequencing
  • Whole Genome Sequencing
  • Array Technology
  • PCR-based Testing
  • FISH
  • Sanger Sequencing
  • Karyotyping

Global Rare Disease Genetic Testing Market, By End User:

  • Research Laboratories & CROs
  • Hospitals & Clinics
  • Diagnostic Laboratories

Global Rare Disease Genetic Testing Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Rare Disease Genetic Testing Market.

Available Customizations:

  • Global Rare Disease Genetic Testings Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Pricing Analysis

6. Global Rare Disease Genetic Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value & Volume
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type (Neurological, CVDs)
    • 6.2.2. By Speciality (Molecular, Biochemical)
    • 6.2.3. By Technology (NGS, PCR-based)
    • 6.2.4. By End User (Research Laboratories & CROs, Hospitals & Clinics, Diagnostic Laboratories)
    • 6.2.5. By Company (2022)
    • 6.2.6. By Region
  • 6.3. Product Market Map

7. North America Rare Disease Genetic Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. Speciality
    • 7.2.3. Technology
    • 7.2.4. By End-Use Industry
    • 7.2.5. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Rare Disease Genetic Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value & Volume
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Speciality
        • 7.3.1.2.3. By Technology
        • 7.3.1.2.4. By End-Use Industry
    • 7.3.2. Mexico Rare Disease Genetic Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value & Volume
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Speciality
        • 7.3.2.2.3. By Technology
        • 7.3.2.2.4. By End-Use Industry
    • 7.3.3. Canada Rare Disease Genetic Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value & Volume
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Speciality
        • 7.3.3.2.3. By Technology
        • 7.3.3.2.4. By End-Use Industry

8. Europe Rare Disease Genetic Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Speciality
    • 8.2.3. By Technology
    • 8.2.4. By End-Use Industry
    • 8.2.5. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Rare Disease Genetic Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value & Volume
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Speciality
        • 8.3.1.2.3. By Technology
        • 8.3.1.2.4. By End-Use Industry
    • 8.3.2. Germany Rare Disease Genetic Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value & Volume
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Speciality
        • 8.3.2.2.3. By Technology
        • 8.3.2.2.4. By End-Use Industry
    • 8.3.3. United Kingdom Rare Disease Genetic Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value & Volume
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. B Speciality
        • 8.3.3.2.3. By Technology
        • 8.3.3.2.4. By End-Use Industry
    • 8.3.4. Italy Rare Disease Genetic Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value & Volume
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Type
        • 8.3.4.2.2. By Speciality
        • 8.3.4.2.3. By Technology
        • 8.3.4.2.4. By End-Use Industry
    • 8.3.5. Spain Rare Disease Genetic Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value & Volume
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Type
        • 8.3.5.2.2. By Speciality
        • 8.3.5.2.3. By Technology
        • 8.3.5.2.4. By End-Use Industry

9. Asia-Pacific Rare Disease Genetic Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Speciality
    • 9.2.3. By Technology
    • 9.2.4. By End-Use Industry
    • 9.2.5. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Rare Disease Genetic Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value & Volume
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Speciality
        • 9.3.1.2.3. By Technology
        • 9.3.1.2.4. By End-Use Industry
    • 9.3.2. India Rare Disease Genetic Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value & Volume
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Speciality
        • 9.3.2.2.3. By Technology
        • 9.3.2.2.4. By End-Use Industry
    • 9.3.3. South Korea Rare Disease Genetic Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value & Volume
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Speciality
        • 9.3.3.2.3. By Technology
        • 9.3.3.2.4. By End-Use Industry
    • 9.3.4. Japan Rare Disease Genetic Testing Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value & Volume
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Type
        • 9.3.4.2.2. By End-Use Industry
    • 9.3.5. Australia Rare Disease Genetic Testing Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value & Volume
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Disease Type
        • 9.3.5.2.2. By Speciality
        • 9.3.5.2.3. By Technology
        • 9.3.5.2.4. By End-Use Industry

10. South America Rare Disease Genetic Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type
    • 10.2.2. By Speciality
    • 10.2.3. By Technology
    • 10.2.4. By End-Use Industry
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Rare Disease Genetic Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value & Volume
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Speciality
        • 10.3.1.2.3. By Technology
        • 10.3.1.2.4. By End-Use Industry
    • 10.3.2. Argentina Rare Disease Genetic Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value & Volume
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Speciality
        • 10.3.2.2.3. By Technology
        • 10.3.2.2.4. By End-Use Industry
    • 10.3.3. Colombia Rare Disease Genetic Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value & Volume
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Speciality
        • 10.3.3.2.3. By Technology
        • 10.3.3.2.4. By End-Use Industry

11. Middle East and Africa Rare Disease Genetic Testing Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value & Volume
  • 11.2. Market Share & Forecast
    • 11.2.1. By Disease Type
    • 11.2.2. By Speciality
    • 11.2.3. By Technology
    • 11.2.4. By End-Use Industry
    • 11.2.5. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Rare Disease Genetic Testing Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value & Volume
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Disease Type
        • 11.3.1.2.2. By Speciality
        • 11.3.1.2.3. By Technology
        • 11.3.1.2.4. By End-Use Industry
    • 11.3.2. Saudi Arabia Rare Disease Genetic Testing Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value & Volume
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Disease Type
        • 11.3.2.2.2. By Speciality
        • 11.3.2.2.3. By Technology
        • 11.3.2.2.4. By End-Use Industry
    • 11.3.3. UAE Rare Disease Genetic Testing Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value & Volume
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Disease Type
        • 11.3.3.2.2. By Speciality
        • 11.3.3.2.3. By Technology
        • 11.3.3.2.4. By End-Use Industry

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Product Launches
  • 13.3. Mergers & Acquisitions

14. PESTLE Analysis

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Product

16. Competitive Landscape

  • 16.1. Business Overview
  • 16.2. Company Snapshot
  • 16.3. Products & Services
  • 16.4. Financials (In case of listed companies)
  • 16.5. Recent Developments
  • 16.6. SWOT Analysis
    • 16.6.1. Centogene N.V.
    • 16.6.2. Invitae Corp.
    • 16.6.3. 3billion, Inc.
    • 16.6.4. Arup Laboratories
    • 16.6.5. Eurofins Scientific
    • 16.6.6. Strand Life Sciences
    • 16.6.7. Ambry Genetics
    • 16.6.8. Perkin Elmer, Inc.
    • 16.6.9. Realm IDX, Inc.
    • 16.6.10. Macrogen, Inc.

17. Strategic Recommendations